Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Cholestanol in Humans

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
VA Office of Research and Development Identifier:
First received: July 3, 2001
Last updated: October 11, 2013
Last verified: October 2013
The treatment of cerebrotendinous xanthomatosis an in born error of bile acid synthesis with chenodeoxycholic acid. Patients with this disease over produce cholestanol and bile acid precursors because of the block in synthesis. Replacement with chenodeoxycholic acid shut down abnormal pathway and reduces elevated level of cholestanol and improves the clinical syndrome.

Condition Intervention
Cerebrotendinous Xanthomatosis
Drug: Chenodeoxycholic Acid

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Official Title: Biologic Significance of Cholestanol in Man

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Enrollment: 0
Study Start Date: October 1999
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Arm 1 Drug: Chenodeoxycholic Acid

Detailed Description:
Cerebrotendinous xanthomatosis is a recessively inherited in born of bile acid synthesis due to a mutation in sterol 27-hydroxylase (CYP27A1). Patients with this disease suffer from xanthomas located in the brain and tendon, accelerated atherosclerosis progression neurologic disease and cataracts. Plasma cholesterol levels are normal but cholestanol and C-27 bile alcohol that precursor of bile acid synthesis accumulate and are believe are responsible for the atherosclerosis, xanthomas and neurologic disease. Analysis of the bile reveal a severe sufficiency of the primary bile acid chenodeoxycholic acid that can not be produce because of the inherited defect. However, replacement of chenodeoxycholic acid in the enterohepatic pool inhibit abnormal bile acid synthesis and reduces the elevated level of cholestanol and C-27 bile alcohol this therapy halt the neurologic disease and prevents symptomatic atherosclerosis developing.

Ages Eligible for Study:   5 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients with clinical and biochemical findings of cerebrotendinous xanthomatosis. Elevated levels of serum cholestanol and bile acid precursors.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00018694

United States, New Jersey
VA New Jersey Health Care System, East Orange
East Orange, New Jersey, United States, 07018
Sponsors and Collaborators
VA Office of Research and Development
Principal Investigator: Gerald Salen VA New Jersey Health Care System, East Orange
  More Information

Responsible Party: VA Office of Research and Development Identifier: NCT00018694     History of Changes
Other Study ID Numbers: GAST-007-99S
Study First Received: July 3, 2001
Last Updated: October 11, 2013

Keywords provided by VA Office of Research and Development:
bile acid synthesis
chenodeoxycholic acid
sterol 27-hydroxylase

Additional relevant MeSH terms:
Xanthomatosis, Cerebrotendinous
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Chenodeoxycholic Acid
Gastrointestinal Agents processed this record on May 25, 2017